New IPOs This Week - Two new stocks are scheduled for subscription this week: Anhui Guqi Down Material Co., Ltd. (Guqi Down Material, 001390) and Zhongce Rubber Group Co., Ltd. (Zhongce Rubber, 603049) [1][3] - Guqi Down Material is a leading company in the down material industry in China, serving major clients in the down clothing and bedding sectors, including Hai Lan Home, Semir Apparel, and Bosideng [1][5] - Zhongce Rubber ranks among the top ten global tire manufacturers and has consistently held the top position in the China Rubber Industry Association's tire company rankings [1][6] Company Profiles - Guqi Down Material focuses on the research, production, and sales of high-specification down products, with a strong emphasis on innovation and environmental sustainability [4][5] - The company has a production capacity that meets international standards, with down content exceeding 80% and a fluffiness index reaching 900in³/30g [5] - Zhongce Rubber specializes in the development and production of various tire products, including all-steel tires and semi-steel tires, and has a strong domestic and international sales network [6][7] Market Position - Guqi Down Material holds a significant market share, supplying approximately 12% of the down clothing market in 2022, and is recognized as one of the four key enterprises in the domestic down processing industry [5] - Zhongce Rubber's products are supplied to major automotive manufacturers such as FAW Jiefang, SAIC General Motors, and BYD, and the company has established a strong brand presence with its "Chaoyang" brand [6][7] Upcoming Listings - The leading company in the A-share market, CATL, is set to list on the Hong Kong Stock Exchange this week, while Jiangsu Hengrui Medicine Co., Ltd. will continue its subscription and list on the Hong Kong Stock Exchange [1][16]

Group 1: Tai Li Technology - Tai Li Technology focuses on new material research and vacuum technology applications, producing a variety of household storage products and related functional materials [1][3] - The company has a market capitalization of 13.85 billion yuan and an issue price of 17.05 yuan per share, with an issuance P/E ratio of 21.55 [2] - Tai Li Technology is the exclusive supplier of vacuum compression bags for China's space missions, with products used in space 25 times, ensuring safety in a vacuum environment [3] - The company has implemented an omnichannel strategy, transitioning from traditional distribution to primarily online sales, covering major platforms in China and internationally [3] Group 2: Weigao Blood Purification - Weigao Blood Purification specializes in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [4][5] - The company has a market capitalization of 26.50 billion yuan and an issue price of 27.57 yuan per share, with an issuance P/E ratio of 24.82 [5] - Weigao Blood Purification holds a 32.5% market share in the domestic hemodialysis device sector, ranking first in the industry [8] - The company has developed a neutral peritoneal dialysis solution in collaboration with a well-known international blood purification company, holding a 3.6% market share in the peritoneal dialysis solution sector [8] - Weigao Blood Purification has established a comprehensive anti-commercial bribery policy and conducts training for employees to mitigate risks associated with unethical practices in the industry [9]

Group 1: Tai Li Technology - Tai Li Technology focuses on new materials research and vacuum technology applications, offering a variety of home storage products and related functional materials [1][4] - The company is the exclusive supplier of compression bags for China's aerospace program, with products used in space 25 times, addressing risks associated with the vacuum environment [4] - Tai Li Technology has implemented a multi-channel strategy, transitioning from traditional distribution to primarily online sales, covering major platforms domestically and internationally [4] - The company has acknowledged past issues with "brushing" and "cashback for reviews," which have been rectified, and it has ceased such practices since 2022 [5] Group 2: Weigao Blood Purification - Weigao Blood Purification specializes in the research, production, and sales of medical products for blood purification, including dialysis machines and related products [5][6] - The company has a market share of 32.5% in the domestic blood dialysis market, leading the industry, and holds a 31.8% share in blood dialysis tubing [9] - Weigao Blood Purification has developed a neutral peritoneal dialysis solution in collaboration with a well-known international company, holding a 3.6% market share in the domestic peritoneal dialysis market [9] - The company plans to invest in various projects, including intelligent production and digital information technology platforms, with a total fundraising target of approximately 12.56 billion yuan [8]

Core Viewpoint - The A-share market will have three new stock subscriptions this week, including Hanbang Technology, Weigao Blood Purification, and Taili Technology, indicating a growing interest in innovative companies within the healthcare and technology sectors [1] Group 1: Hanbang Technology - Hanbang Technology is a leading supplier of chromatography separation and purification equipment in China, particularly in the production-grade small molecule drug separation market, holding a market share of approximately 39.2% [3] - The company has developed a comprehensive product matrix for both small and large molecule drug separation and purification equipment, catering to industrial production and laboratory research [2] - Hanbang Technology's revenue for 2022, 2023, and 2024 is projected to be 482 million, 619 million, and 691 million yuan, respectively, with net profits of 39 million, 51 million, and 79 million yuan [3] Group 2: Weigao Blood Purification - Weigao Blood Purification focuses on the research, production, and sales of medical products for blood purification, with a diverse product line including blood dialysis machines and accessories [4] - The company holds a leading market share in the domestic blood dialysis sector, with 32.5% in blood dialysis devices and 31.8% in blood dialysis tubing [4] - Revenue projections for Weigao Blood Purification for 2022, 2023, and 2024 are 3.426 billion, 3.532 billion, and 3.604 billion yuan, respectively, with net profits of 315 million, 442 million, and 449 million yuan [5] Group 3: Taili Technology - Taili Technology specializes in new material research and vacuum technology applications, being the exclusive supplier of compression bags for China's aerospace sector [6] - The company has implemented a multi-channel sales strategy, transitioning from traditional distribution to a primarily online sales model, while also maintaining strong offline retail partnerships [7] - Revenue forecasts for Taili Technology for 2022, 2023, and 2024 are 638 million, 835 million, and 1.02 billion yuan, respectively, with net profits of 59 million, 85 million, and 88 million yuan [7]